GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...

GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable ...

The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes ...

DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...

New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

DexCom expects 2026 total revenue to be in a range of $5.16 billion to $5.25 billion, representing growth of 11% to 13% for the year. Sylvain indicated, "This guidance assumes continued strong ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) announced new AI-enabled features ...

Urinary tract infections (UTIs) are among the most common bacterial infections, with catheter-associated UTIs accounting for ...

Early clinical trials established the safety and feasibility of closed-loop insulin delivery, but the 2019 iDCL trial1 marked the first large, outpatient, randomised, controlled trial to show a ...